Dermira Inc (DERM):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Dermira Inc (DERM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8230
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Dermira Inc (Dermira) is a biopharmaceutical company that identifies, develops and commercializes therapeutic solutions for the treatment of dermatologic diseases, such as hyperhidrosis, acne vulgaris and atopic dermatitis. The company’s product includes QBREXZA (glycopyrronium) cloth, an anticholinergic indicated for the treatment of primary axillary hyperhidrosis in pediatric and adult patients. Its pipeline products include Lebrikizumab, an injectable humanized monoclonal antibody intended for the treatment of moderate-to-severe atopic dermatitis; and other early-stage research programs in other areas of dermatology. Dermira is headquartered in Menlo Park, California, the US.

Dermira Inc (DERM) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dermira Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Dermira Inc, Medical Devices Deals, 2012 to YTD 2018 10
Dermira Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Dermira Inc, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Dermira Raises USD0.5 Million in Venture Financing 13
Dermira Raises USD1.5 Million in Venture Financing 14
Dermira Raises USD51 Million In Series C Venture Financing 15
Dermira Raises US$35 Million In Series B Financing 17
Dermira Raises USD25 Million in Venture Financing 19
Dermira Raises US$34 Million In Venture Financing 20
Partnerships 21
ImaBiotech Enters into Agreement with Dermira 21
Licensing Agreements 22
Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 22
Maruho Enters into Licensing Agreement with Dermira for DRM04 24
Dermira Enters into Option Agreement with Takeda Pharma 25
Dermira Enters Into Licensing Agreement with Rose U 26
Equity Offering 27
Dermira Raises USD193.8 Million in Public Offering of Shares 27
Dermira Raises USD145 Million in Public Offering of Shares 29
Dermira Raises USD111.3 Million in Public Offering of Shares 31
Dermira Raises USD125 Million in IPO of Shares 33
Dermira Raises USD7.5 Million in Private Placement of Shares 35
Debt Offering 37
Dermira Raises USD287.5 Million in Private Placement of 3% Notes Due 2022 37
Dermira Inc – Key Competitors 38
Dermira Inc – Key Employees 39
Dermira Inc – Locations And Subsidiaries 40
Head Office 40
Recent Developments 41
Financial Announcements 41
Aug 06, 2018: Dermira reports second quarter 2018 financial results and provides corporate update 41
May 03, 2018: Dermira Reports First Quarter 2018 Financial Results and Provides Corporate Update 43
Feb 22, 2018: Dermira Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 45
Nov 06, 2017: Dermira Reports Third Quarter 2017 Financial Results 47
Aug 07, 2017: Dermira Reports Second Quarter 2017 Financial Results and Provides Corporate Update 48
May 08, 2017: Dermira Reports First Quarter 2017 Financial Results and Provides Corporate Update 49
Feb 28, 2017: Dermira Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 51
Corporate Communications 53
Jan 04, 2017: Dermira Elects Emmanuel Caeymaex to Board of Directors 53
Other Significant Developments 54
Jan 06, 2017: Dermira Provides Corporate Update 54
Appendix 56
Methodology 56
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Dermira Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dermira Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dermira Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Dermira Inc, Medical Devices Deals, 2012 to YTD 2018 10
Dermira Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Dermira Raises USD0.5 Million in Venture Financing 13
Dermira Raises USD1.5 Million in Venture Financing 14
Dermira Raises USD51 Million In Series C Venture Financing 15
Dermira Raises US$35 Million In Series B Financing 17
Dermira Raises USD25 Million in Venture Financing 19
Dermira Raises US$34 Million In Venture Financing 20
ImaBiotech Enters into Agreement with Dermira 21
Dermira Enters into Licensing Agreement with F. Hoffmann-La Roche and Genentech for Lebrikizumab 22
Maruho Enters into Licensing Agreement with Dermira for DRM04 24
Dermira Enters into Option Agreement with Takeda Pharma 25
Dermira Enters Into Licensing Agreement with Rose U 26
Dermira Raises USD193.8 Million in Public Offering of Shares 27
Dermira Raises USD145 Million in Public Offering of Shares 29
Dermira Raises USD111.3 Million in Public Offering of Shares 31
Dermira Raises USD125 Million in IPO of Shares 33
Dermira Raises USD7.5 Million in Private Placement of Shares 35
Dermira Raises USD287.5 Million in Private Placement of 3% Notes Due 2022 37
Dermira Inc, Key Competitors 38
Dermira Inc, Key Employees 39

List of Figures
Dermira Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Dermira Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Dermira Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Dermira Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Dermira Inc (DERM):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Airgas Inc-医療機器分野:企業M&A・提携分析
    Summary Airgas Inc (Airgas), a subsidiary of Air Liquide S.A., is a supplier of industrial, medical, specialty gases and related equipment. The company also provides welding equipment, safety products, ammonia products, refrigerants, nitrous oxide, atmospheric gases, carbon dioxide and dry ice, weld …
  • Steel Excel Inc (SXCL):企業の財務・戦略的SWOT分析
    Summary Steel Excel Inc (Steel Excel) is a provider of technology consulting and business development solutions. The company’s services comprise rogue pressure services, sun well services, black hawk energy services, functional fitness facilities, sports training, strength and conditioning gym facil …
  • Holland Board of Public Works:企業の戦略的SWOT分析
    Holland Board of Public Works - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • TClarke Plc (CTO):企業の財務・戦略的SWOT分析
    TClarke Plc (CTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Emcure Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Emcure Pharmaceuticals Ltd (Emcure) develops, manufactures and markets a range of pharmaceutical products worldwide. The company specializes in the development and manufacture of differentiated pharmaceutical products. It also manufactures active pharmaceutical ingredients (APIs) primarily f …
  • MEI Pharma Inc (MEIP):企業の財務・戦略的SWOT分析
    MEI Pharma Inc (MEIP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • UNeMed Corp:医療機器:M&Aディール及び事業提携情報
    Summary Unemed Corp (Unemed), a subsidiary of University of Nebraska Medical Center, is a healthcare service provider. The company offers services such as inventions, material transfer, confidentiality, intellectual property, startup formation and licensing process. Its technologies include therapeu …
  • UPL Ltd (UPL):企業の財務・戦略的SWOT分析
    UPL Ltd (UPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Renaissance Oil Corp (ROE):石油・ガス:M&Aディール及び事業提携情報
    Summary Renaissance Oil Corp (Renaissance Oil), formerly San Antonio Ventures Inc is an oil and gas exploration and development company that acquires and develops high potential shale and mature fields in Mexico. The company utilizes seismic technology and advanced structural interpretation for the …
  • Perpetual Energy Inc. (PMT)-石油・ガス分野:企業M&A・提携分析
    Summary Perpetual Energy Inc. (Perpetual Energy) is an exploration and production company. It explores, develops and produces from shallow gas, liquids-rich gas, heavy oil, bitumen and other assets. The company produces light and medium crude oil, heavy oil natural gas and natural gas liquids. Perpe …
  • Singareni Collieries Co Ltd:企業の戦略・SWOT・財務情報
    Singareni Collieries Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Singareni Collieries Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Bayer AG (BAYN):製薬・医療:M&Aディール及び事業提携情報
    Summary Bayer AG (Bayer) carries out the research, development, production and commercialization of products for human and animal health care, and agriculture. It provides medicines for cardiovascular diseases, women’s health, cancer, hematology, ophthalmology and other indications. The company's pr …
  • Canadian Broadcasting Corp:企業の戦略的SWOT分析
    Canadian Broadcasting Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Netflix, Inc.:企業の戦略・SWOT・財務情報
    Netflix, Inc. - Strategy, SWOT and Corporate Finance Report Summary Netflix, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Booking Holdings Inc:企業の戦略・SWOT・財務分析
    Booking Holdings Inc - Strategy, SWOT and Corporate Finance Report Summary Booking Holdings Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Caspian Energy Inc:企業の戦略的SWOT分析
    Caspian Energy Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Neos Therapeutics Inc (NEOS):製薬・医療:M&Aディール及び事業提携情報
    Summary Neos Therapeutics Inc (Neos Therapeutics), formerly Neostx Inc, develops, manufactures, and commercializes branded pharmaceuticals. The company’s portfolio includes Adzenys XR-ODT that is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients of six years …
  • NanoString Technologies Inc (NSTG)-医療機器分野:企業M&A・提携分析
    Summary NanoString Technologies Inc (NanoString) is a provider of life science products and tools for translational research and molecular diagnostics. The company's products portfolio includes sprint profiler, Dx analysis system with flex, MAX analysis system, protein assays, solid tumor assays, ge …
  • Tricida Inc (TCDA):製薬・医療:M&Aディール及び事業提携情報
    Summary Tricida Inc (Tricida), formerly Trilypsa Inc is a clinical-stage pharmaceutical and drug discovery company. The company discovers and develops novel non-absorbed therapies for the treatment of renal, metabolic and cardiovascular diseases. Its lead drug candidate TRC101, is under clinical dev …
  • Fabric Development Inc:企業の戦略的SWOT分析
    Fabric Development Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆